MRNA news · MRNA stock

Kymera's KT-621 Has 'Oral Dupixent' Potential, but Valuation Limits Upside, RBC Says

Yahoo Finance · Sep 2, 2026 · Moderna Inc (MRNA)

Kymera Therapeutics' (KYMR) KT-621 could validate its "oral Dupixent" potential, but with a roughly

Original at Yahoo Finance

Not investment advice. Cached headline, not a full reprint.